AFMDQ (Affimed NV) Ending Cash Position: $8.22 Mil (As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AFMDQ Affimed NV AFMDQ
16 GF Score
Price $0.00
View Full Analysis

What is Affimed NV Ending Cash Position?

Affimed NV AFMDQ 16 Ending Cash Position is $8.22 Mil as of Sep. 2024. GuruFocus rates AFMDQ with a GF Score™ of 16/100.

Affimed NV's Ending Cash Position for the quarter that ended in Sep. 2024 was $8.22 Mil.

Affimed NV's quarterly Ending Cash Position declined from Mar. 2024 ($15.60 Mil) to Jun. 2024 ($11.59 Mil) and declined from Jun. 2024 ($11.59 Mil) to Sep. 2024 ($8.22 Mil).

Affimed NV's annual Ending Cash Position declined from Dec. 2021 ($223.31 Mil) to Dec. 2022 ($201.57 Mil) and declined from Dec. 2022 ($201.57 Mil) to Dec. 2023 ($42.02 Mil).

Affimed NV Ending Cash Position Related Terms

Affimed NV Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Affimed NV's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affimed NV Ending Cash Position Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 105.82 178.66 223.31 201.57 42.02

Affimed NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.04 42.02 15.60 11.59 8.22
AFMDQ
16GF Score
Affimed NV AFMDQ
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Affimed NV Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Affimed NV's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=207.509+-165.493
=42.02

Affimed NV's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=11.947+-3.728
=8.22

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $8.22 Mil mean?
Affimed NV (AFMDQ) has a Ending Cash Position of $8.22 Mil as of Sep. 2024. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Affimed NV and its competitors.
Is Affimed NV's Ending Cash Position too high?
Affimed NV's current Ending Cash Position is $8.22 Mil. Overall, Affimed NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Affimed NV's Ending Cash Position compare to SYRS and BTAX?
Affimed NV's Ending Cash Position of $8.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Affimed NV and its competitors. Affimed NV's current Ending Cash Position is $8.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Affimed NV stock overvalued right now?
Affimed NV (AFMDQ) has a current Ending Cash Position of $8.22 Mil. The current Ending Cash Position is $8.22 Mil. Affimed NV's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Affimed NV (AFMDQ), the current Ending Cash Position is $8.22 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Affimed NV Business Description

Address Gottlieb-Daimler-Strabe 2, Mannheim, BW, DEU, 68165
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
16GF Score

Get the complete analysis for AFMDQ

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price